Chylous effusion (Q42966): Difference between revisions

From determinar.ia.br - Determine suas informações
Created a new Item
 
Changed an Item
 
(7 intermediate revisions by the same user not shown)
description / pt-brdescription / pt-br
 
Um derrame quiloso (quilotórax) é definido pela presença de quilo no espaço pleural como resultado de obstrução ou ruptura do ducto torácico ou de um de seus principais tributários. Uma concentração de triglicérides >110 mg/dL é virtualmente diagnóstica, mas a presença de quilomícrons confirma este diagnóstico. No entanto, um quilotórax definido por estes critérios representa um grupo heterogêneo de entidades clínicas. A presença de quilomícrons ou níveis de triglicérides >110 mg/dL em um derrame pleural devem ser considerados como evidência de vazamento de quilo com significado clínico indeterminado. Muitos casos de derrame quiloso podem estar associados a outras causas de acúmulo de líquido pleural.
description / endescription / en
 
A chylous effusion (chylothorax) is defined by the presence of chyle in the pleural space resulting from obstruction or disruption of the thoracic duct or one of its major tributaries. A triglyceride concentration > 110 mg/dL is virtually diagnostic, but the presence of chylomicrons confirms the diagnosis. However, a chylothorax defined by these criteria represents a heterogeneous group of clinical entities. The presence of chylomicrons or triglyceride levels > 110 mg/dL in a pleural effusion should be considered evidence of chyle leakage of indeterminate clinical significance. Many cases of a chylous effusion may be associated with other causes of pleural fluid formation.
Property / Canonical URI
 
Property / Canonical URI: https://id.who.int/icd/entity/693433074 / rank
 
Normal rank
Property / CURIE
 
CID11:CB24
Property / CURIE: CID11:CB24 / rank
 
Normal rank
Property / Canary Token
 
dki-india-CB24
Property / Canary Token: dki-india-CB24 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank
Property / Linked ICD 10
 
Property / Linked ICD 10: J94.0 / rank
 
Normal rank

Latest revision as of 09:44, 13 August 2026

A chylous effusion (chylothorax) is defined by the presence of chyle in the pleural space resulting from obstruction or disruption of the thoracic duct or one of its major tributaries. A triglyceride concentration > 110 mg/dL is virtually diagnostic, but the presence of chylomicrons confirms the diagnosis. However, a chylothorax defined by these criteria represents a heterogeneous group of clinical entities. The presence of chylomicrons or triglyceride levels > 110 mg/dL in a pleural effusion should be considered evidence of chyle leakage of indeterminate clinical significance. Many cases of a chylous effusion may be associated with other causes of pleural fluid formation.
Language Label Description Also known as
default for all languages
CB24
    English
    Chylous effusion
    A chylous effusion (chylothorax) is defined by the presence of chyle in the pleural space resulting from obstruction or disruption of the thoracic duct or one of its major tributaries. A triglyceride concentration > 110 mg/dL is virtually diagnostic, but the presence of chylomicrons confirms the diagnosis. However, a chylothorax defined by these criteria represents a heterogeneous group of clinical entities. The presence of chylomicrons or triglyceride levels > 110 mg/dL in a pleural effusion should be considered evidence of chyle leakage of indeterminate clinical significance. Many cases of a chylous effusion may be associated with other causes of pleural fluid formation.

      Statements

      CID11:CB24
      0 references
      dki-india-CB24
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references